Future Studies
- More Diode Array Spectrophotometry trials
- In vitro/in vivo studies
- Investigate other proposed pathways
- AMPK or other enzymes in gluconeogenesis
- Investigate other metformin uses
- Improves Breast Cancer survival (Quinn, Kitagawa, Memmott, Gills, Dennis, 2013)
- Increased ovulation in PCOS
- Improves Breast Cancer survival (Quinn, Kitagawa, Memmott, Gills, Dennis, 2013)
- Comparative study of metformin and other biguanides
Through research, a way to inhibit gluconeogenesis has been found. This could lead to other treatments that target pyruvate carboxylase to inhibit gluconeogenesis. By doing this research, patient outcomes could be improved for type II diabetes and improve the lives of those patients. It is important to study metformin and its effects. The more we understand about it, the more we can help diabetes patients.
Figure 13: This is a drug called phenformin. A drug with more lethal side effects than metformin, it was banned shortly after its release in the United States. Through the synthesis of more biguanides, these side effects could be reduced.
Acknowledgments
- Matt DeSelm for helping me to write my paper
- Andrea Solís for allowing me to do experimentation with her
- Lori Ball for allowing me to experience this amazing opportunity
- DC and Saba Wolde for giving me feedback on my paper a presentation
- Dr. Richard Hyslop for allowing us to use his lab
- Dr. Patrick Burns for allowing us to use his lab and teaching us incredible topics
- Dr. Michael Mosher for helping us work the NMR machine
- UNC Department of Chemistry and Biochemistry for allowing me to use their equipment
- Rollie R. Kelley Family Foundation, and Xcel Energy for sponsoring my research and time at FSI
If you have any questions, email me at "[email protected]."
References
American Diabetes Association. (5 April 2017). Statistics About Diabetes. Retrieved from http://www.diabetes.org/diabetes-basics/statistics/
Diabetes Canada. (n.d). History of Diabetes. Retrieved from http://www.diabetes.ca/about-diabetes/history-of-diabetes
United States National Library of Medicine. (5 July 2017). Diabetes Type 2. Retrieved from https://medlineplus.gov/diabetestype2.html
University of California San Francisco. (n.d). Table of Medications. Retreived from https://dtc.ucsf.edu/types-of-diabetes/type2/treatment-of-type-2-diabetes/medications-and-therapies/type-2-non-insulin-therapies/table-of-medications/
He, L. E, Fredic. Windisford. (3, February, 2015). Metformin Action: Concentrations Matter. Cell Metabolism, 21(2), 159-162. doi: 10.1016/j.cmet.2015.01.003
United States National Library of Medicine. (2 June 2017). DRUG RECORD: METFORMIN. Retrieved from https://livertox.nih.gov/Metformin.htm
National Institute of Health. (5 July 2017). Diabetes Type 2. Retrieved from https://medlineplus.gov/ency/article/000313.htm
National Institute of Diabetes and Digestive and Kidney Diseases. (n.d). Prediabetes & Insulin Resistance. Retrieved from https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance
University of California, San Francisco. (n.d). The Liver & Blood Sugar. Retreived from https://dtc.ucsf.edu/types-of-diabetes/type2/understanding-type-2-diabetes/how-the-body-processes-sugar/the-liver-blood-sugar/
Foretz, M. Hébrard, S. Leclerc, J. Zarrinpashneh, E. Soty, M. Mithieux, G. Sakamoto, K. Andreelli, F. Viollet, B. (23 June 2010). Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. The Journal of Clinical Investigation, 120(7):2355–2369. doi: 10.1172/JCI40671
United States National Library of Medicine. (15 April 2017). Metformin. Retrieved from https://medlineplus.gov/druginfo/meds/a696005.html
AJ, S. (May 1996). Clinical pharmacokinetics of metformin. Clinical Pharmacokinetics, 30(5):359-71
Cao, J. Meng, S. Chang, E. Beckwith-Fickas, K. Xiong, L. Cole, R. Radovick, S. Wondisford, S. E, R. He, L. (2014 July 25). Antidiabetic
Drug Metformin Suppresses Gluconeogenesis: Low Concentrations of Metformin Suppress Glucose Production in Hepatocytes through AMP-activated Protein Kinase (AMPK). The Journal of Biological Chemistry, 289: 20435-20446. doi:10.1074/jbc.M114.567271
Baur, J. Birnbaum, M. (5 August 2014). Control of Gluconeogenesis by Metformin: Does Redox Trump Energy Charge?. Cell Metabolism, 20(2): 197-199. doi:10.1016/j.cmet.2014.07.013
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X., Braddock, D. T., Albright, R. A., . Shulman, G. I. (2014). Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature, 510(7506), 542-6. Retrieved from http://www.nature.com/nature/journal/v510/n7506/full/nature13270.html
Caton, P., Nayuni, N., Kieswich, J., Khan, N., Yaqoob, M., & Corder, R. (2010). Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. Journal of Endocrinology, 205(1), 97-106. doi:10.1677/JOE-09-0345
Rensselaer Polytechnic University. (n.d). Gluconeogenesis; Regulation of Glycolysis & Gluconeogenesis. Retreived from https://www.rpi.edu/dept/bcbp/molbiochem/MBWeb/mb1/part2/gluconeo.htm
Mihaylova, M. M., & Shaw, R. J. (2011). The AMP-activated protein kinase (AMPK) signaling pathway coordinates cell growth, autophagy, & metabolism. Nature Cell Biology, 13(9), 1016–1023. doi: 10.1038/ncb2329
Samuel, V. T., Beddow, S. A., Iwasaki, T., Zhang, X., Chu, X., Still, C. D., . . . Shulman, G. I. (2009). Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with type 2 diabetes. Proceedings of the National Academy of
Sciences of the United States of America, 106(29), 12121-12126. doi:10.1073/pnas.0812547106
Ravi, K. (2015 May 30). Gluconeogenesis for medical school [PowerPoint slides]. Retrieved July 3, 2017, from SlideShare website: http://www.slideshare.net /ravikiran35977897/gluconeogenesis-for-medical-school
New York Times. (25 June 2017). Type 2 Diabetes. Retreived from http://www.nytimes.com/health/guides/disease/type-2-diabetes/medications.html
Cheng, H. Qi, R. Paudel, H. Zhu, H. (2011). Regulation and Function of Protein Kinases and Phosphatases. Enzyme Research, 2011, 1-3. doi:10.1073/pnas.0812547106
Attwood, P. (1995). The structure and the mechanism of action of pyruvate carboxylase. The International Journal of Biochemistry & Cell Biology, 27(3), 231-249.
Quinn, B. Kitagawa, H. Memmott, M. Gills, J. Dennis, P. (2013 Sep). Repositioning metformin for cancer prevention and treatment. Trends in Endocrinology and Metabolism, 24(9), 469-80. doi: 10.1016/j.tem.2013.05.004
Mihaylova, M. Shaw, R. (2 Sep 2011). The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nature Cell Biology. 13(2011), 1016–1023. doi: 10.1038/ncb2329
Mráček, T. . Drahota, Z. Houštěk, J. (March 2013). The function and the role of the mitochondrial glycerol-3-phosphate dehydrogenase in mammalian tissues. Biochimica et Biophysica Acta (BBA) - Bioenergetics. 1827(3), 401-410. doi: 10.1016/j.bbabio.2012.11.014
Miles, B. (n.d). Integration of Metabolism. Retreived from https://www.tamu.edu/faculty/bmiles/lectures/integration.pdf
Zhou, G. Myers, R. Li, Y. Chen, Y. Shen, X. Fenyk-Melody, J…Moller, D. (2001 Oct 15). Role of AMP-activated protein kinase in mechanism of metformin action. The Journal of Clinical Investigation, 108(8), 1167–1174. doi: 10.1172/JCI13505
Lashen, H. (Jun 2010). Role of metformin in the management of polycystic ovary syndrome. Therapeutic advances in endocrinology and metabolism, 1(3), 117–128. doi: 10.1177/2042018810380215Veneziale, C. M., Donofrio, J. C., & Nishimura, H. (1983). The concentration of P-enolpyruvate carboxykinase protein in murine tissues in diabetes of chemical and genetic origin. Journal of Biological Chemistry, 258(23), 14257. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/6643479